Avidity Biosciences, Inc. (RNA)
NEUTRALFundamental
36
मूल्य
$13.85
मार्केट कैप
$226M
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$36M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-448M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
-
कुल इक्विटी
$1.69B
कुल देनदारियाँ
$269M
Current Ratio
8.73
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$25.00
वर्तमान मूल्य
$13.85
Margin of Safety
+44.6%
Fair Value सीमा
$23.75 - $26.25
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-40.5%
P/B Ratio
1.09
P/FCF
-
Gross Margin
-
ROIC
-153.3%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-153.3%
WACC
10.2%
ROIC − WACC
-163.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (6)
- P/B Ratio 1.09
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 86% Buy
- Earnings Surprise avg 8.5%
फेल (9)
- EPS shows upward trend
- ROIC -153.3%
- Operating Margin -1343.1%
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -40.3%
- Share Dilution 88.9%
- Net Margin Trend -3650.4% vs -2219.9%
- Piotroski F-Score 3/9
अनुपलब्ध (12)
- Historical price data insufficient
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Ms. Kathleen P. Gallagher | President, CEO & Director | 44 |
| Mr. Brendan Winslow | Chief Financial Officer | 37 |
| Dr. Husam Younis Ph.D., Pharm.D. | Chief Scientific Officer | 51 |
| Ms. Stephanie Kenney | Chief Corporate Affairs Officer | 47 |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer | 58 |
| Ms. Rocio Martin Hoyos | Chief Strategy Officer | 42 |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for RNA, sourced from Markets Gazette.